Latest Patrys (ASX:PAB) News

Patrys Limited has formalized the redundancy of CEO Dr James Campbell, with a $535,877 payout partly converted into shares pending shareholder approval. Dr Campbell will continue as a non-executive director.

Patrys Limited has raised $358,362 through a share placement and announced significant board changes, including the appointment of Dr Anton Uvarov and Mr Peter Christie, alongside making the CEO role redundant.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Patrys Limited has halted plans for a Phase 1 trial of PAT-DX1 following disappointing GMP production results, pivoting its development efforts towards PAT-DX3 and exploring new partnerships.